Last update: 02.11.2024 13:25 (GMT+2)

J.Molner (05.12.2023)

Tallinn market | First North Baltic Share List

MOLNR  |  ISIN EE3100109034

Health Care

J.Molner

J.Molner

Name: J.Molner AS
Core business: Biotechnology
Date of registration: 22.09.2022
Auditor: Grant Thornton Baltic OÜ
Date of Admission to Trading: 10.11.2022 (First North Share List)
Certified adviser: Ellex Raidla Law Firm
Market: Nasdaq Tallinn
Other listings: -

Management Board:
Jason Michael Atticus Grenfell-Gardner

Supervisory Board:
Karita Sall, Yoann John Ricau, Martin Wilson

Background Information
J. Molner is a pharmaceutical company with Estonian roots aimed at providing its customers with the highest level of generic drugs for specialty generic pharmaceuticals with a focus on the USA and Canadian markets. We also provide our service clients with analytical chemistry services and cost-saving commercial stability solutions. J. Molner’s activities are based on its high-tech laboratory capable of performing a wide range of chemical analyses and studies that may be required for drug development and verifying the quality and content of various pharmaceuticals. J. Molner has the required know-how, personnel, and means to develop various generic drugs with a core focus on sterile injectable and non-sterile topical formulations.

Contact Details
Address: Akadeemia tee 21/5, 12618 Tallinn, Estonia
E-mail: jmolner@jmolner.com
Internet webpage: https://www.jmolner.com/
Contact person: Jason Michael Atticus Grenfell-Gardner (Chairman of the Management Board)

Documents

Tradable Assets

Shares
Bonds
Funds

Market information

Statistics
Trading
Indexes
Auctions

Market Regulation

Rules and Regulations
Surveillance

Get Started

For Companies
For Investors
For Brokers/Members
For First North Advisers

News

Nasdaq News
Issuer News
Calendar

About Us

Nasdaq Baltic Market
Offices